Clinical trials: Ovarian
Low Ovarian Reserve, Poor Quality Oocytes
Improving the Reproductive Outcome of Poor Quality Ova by Injection of Autologous Somatic Mitochondria
A prospective randomized controlled trial (RCT) to determine the effect of injecting an autologous somatic mitochondria concentrate, together with the spermatozoon during ICSI, into oocytes of older and or poor prognosis in vitro…
- Trial name
- NCT01631578
- Testing
- Injection of an autologous mitochondria to the oocyte.
- Where
- Israel
- Sponsor
- Hadassah Medical Organization
Polycystic Ovary Syndrome
Evaluation of Endocrine and Metabolic Parameters in the New Diagnostic Phenotypes of Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) is a very frequent endocrine disease of women in reproductive age, with an estimated prevalence of 5 to 10 % according to the studied population.
- Trial name
- NCT00784615
- Testing
- Blood samples, transvaginal ultrasound
- Where
- Argentina
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional de Córdoba
Premature Ovarian Failure，
Stem Cell Therapy Combined Hormone Replacement Therapy in Patients With Premature Ovarian Failure
Premature ovarian failure (POF) refers the occurrence of amenorrhoea, elevated serum gonadotrophins and hypoestrogenism levels in female before the age of 40.
- Trial name
- NCT01742533
- Testing
- human umbilical cord mesenchymal stem cells, hUCMSCs and hCBMNCs, human cord blood mononuclear cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shenzhen Beike Bio-Technology Co., Ltd.
Ovarian Cancer
Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer
This study aims to understand whether it is possible to predict the effectiveness of maintenance treatment with PARP inhibitors following first-line chemotherapy in ovarian cancer, and thus better target the patients who benefit…
- Trial name
- KELI-PAOLA (NCT06660147)
- Where
- 24 sites in France, Monaco
- Volunteers
- 243 people
- Sponsor
- ARCAGY/ GINECO GROUP
Ovarian Cancer
Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients
Ovarian cancer ranks third in the incidence of gynecologic malignancies, while mortality ranks first. The tumor marker CA125 is the most concerned tumor marker in the clinical monitoring prognosis of ovarian cancer, and an…
- Trial name
- NCT06182917
- Where
- China
- Volunteers
- 35 people
- Sponsor
- West China Second University Hospital
Breast Cancer, Ovarian Cancer
Awareness and Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis for Inherited Breast/Ovarian Cancer Risk
We are inviting you to participate in a study of how people who have had genetic counseling for breast/ovarian cancer risk feel about certain reproductive technologies, preimplantation genetic diagnosis (PGD) and prenatal genetic…
- Trial name
- NCT00735150
- Testing
- questionnaire, interview
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum
RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. Goserelin may interfere with the growth factor and may stop the tumor from growing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00012090
- Testing
- bicalutamide, goserelin acetate
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer, Head and Neck Cancer
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
This is a multicenter, open label, Phase 2 study of TJ004309 in combination with atezolizumab in patients with advanced or metastatic solid tumors.
- Conditions
- Ovarian Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer, Gastrointestinal Cancer
- Trial name
- NCT05001347
- Testing
- TJ004309
- Where
- 15 sites in United States
- Volunteers
- 25 people
- Sponsor
- I-Mab Biopharma US Limited
Endometrial Neoplasms, Ovarian Neoplasms
STELLA 2 Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian Cancer
The purpose of this study is to determine whether or not there are more complications in the extraperitoneal compared with the transperitoneal approach for laparoscopic aortic lymphadenectomy for the surgical staging of…
- Trial name
- STELLA-2 (NCT02676726)
- Testing
- Extraperitoneal Laparoscopic aortic lymphadenectomy, Transperitoneal Laparoscopic aortic lymphadenectomy
- Where
- Spain
- Volunteers
- 208 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
High Grade Serous Ovarian Cancer
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
The objective of this study is to explore the integration of in vivo and ex vivo of MRI with histology and molecular assessments to advance non-invasive characterization of tumor heterogeneity in high-grade serous ovarian cance
- Trial name
- MR-O-MICS (NCT06084195)
- Testing
- Blood sample and tissue sample
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Ovarian Cancer
Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002477
- Testing
- carboplatin, cisplatin, cyclophosphamide
- Where
- United Kingdom
- Sponsor
- Medical Research Council
High-grade Serous Ovarian Carcinoma (HGSOC)
Artificial Intelligence-guided Precision Treatment of High-grade Serous Ovarian Carcinoma
The subjects of this study are patients with high-grade serous ovarian cancer who have undergone surgical resection. The aim is to construct an artificial intelligence model for predicting postoperative recurrence, metastasis and…
- Trial name
- AI-PTHGSOC (NCT07721675)
- Testing
- No Intervention: Observational Cohort
- Volunteers
- 1,300 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Poor Ovarian Reserve
Effect of Growth Hormone Injection on the IVF/ICSI Outcome of Patients With Poor Ovarian Reserve.
Declined fertility and ovarian reserve in older women are associated with lower density of Growth hormone (GH) receptors and dysregulation in GH secretion.
- Trial name
- NCT04588844
- Testing
- Polyethylene Glycol Recombinant Human Somatropin
- Volunteers
- 200 people
- Sponsor
- Shandong University
Cancer, Cancer Symptom Clusters
Clinical Evaluation of the Tiaoshen Anti-Cancer Regimen in Treating Psycho-Neurological Symptom Cluster in Ovarian Cancer
The academic community generally believes that cancer symptom clusters (CSCs) are not independent diseases, but a group of symptoms that accompany cancer patients.
- Trial name
- NCT07050563
- Testing
- Compound Ciwujia Granules, Standard treatment protocol for ovarian cancer combined with psychological intervention.
- Volunteers
- 316 people
- Sponsor
- Shanghai Municipal Hospital of Traditional Chinese Medicine
Ovarian Cancer, Fallopian Tube
A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
The purpose of this study is to test the safety of a combination of an investigational WT1 vaccine and another drug called nivolumab. This is the first time that the WT1 vaccine and nivolumab are being used in combination.
- Conditions
- Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer, Recurrent Ovarian Cancer
- Trial name
- NCT02737787
- Testing
- WT1 Vaccine, Nivolumab, NY-ESO-1 Vaccine
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cervical Cancer, Lung Cancer
Internet-based System for Cancer Patients to Self-report Toxicity
Cancer patients may develop side effects during treatment, such as nausea, pain, fatigue, diarrhea, constipation, or shortness of breath.
- Conditions
- Cervical Cancer, Lung Cancer, Prostate Cancer, Vaginal Cancer
- Trial name
- NCT00578006
- Testing
- Questioners, STAR website
- Where
- United States
- Volunteers
- 1,007 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Psoriasis, Anti Mullerian Hormone
Ovarian Reserve in Patients With Psoriasis
Psoriasis is a common autoimmune disease. It affects women of all ages including reproductive years. Autoimmune diseases including psoriasis are linked to premature ovarian reserve.
- Conditions
- Psoriasis, Anti Mullerian Hormone, Ovarian Reserve
- Trial name
- NCT03492632
- Testing
- Hormone panel
- Where
- Turkey (Türkiye)
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
This phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs.
- Conditions
- Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma
- Trial name
- NCT04739800
- Testing
- Biospecimen Collection, Cediranib Maleate, Computed Tomography
- Where
- 391 sites in United States, Puerto Rico
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Ovarian Cancer
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
This clinical trial adapts and evaluates the effectiveness of a family history screening program (GA CORE) for increasing uptake of genetic screening for BRCA-associated cancers in women who have received care in rural public…
- Trial name
- RSPH5973-23 (NCT06760507)
- Testing
- Adapted Family History Screening Program
- Where
- United States
- Volunteers
- 3,209 people, healthy volunteers welcome
- Sponsor
- Emory University
Malignant Solid Tumour, Ovarian Cancer
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Overall Design: This is a multicenter, open-label, Phase 1/2 study which will be conducted in three arms (as described below). Each arm will be conducted in two parts: a Phase 1 part which will include dose escalation and a Phase…
- Conditions
- Malignant Solid Tumour, Ovarian Cancer, Triple Negative Breast Cancer, Advanced Melanoma
- Trial name
- NCT01618136
- Testing
- E7449 alone, E7449 plus TMZ, E7449 plus carboplatin and paclitaxel
- Where
- 2 sites in United Kingdom
- Volunteers
- 41 people
- Sponsor
- Eisai Limited